AbbVie is about to release earnings. Ponder the Bear Case Scenario:
AbbVie to lose close to $2 billion in sales over the 2013-14 time period as patents expire on cardiovascular drugs Niaspan, Trilipix, and Tricor. Not good.
Poor competitive position of HIV drug Kaletra will likely mean a slow sales decline over the next four years, creating a drag on overall company growth.
Besides the hepatitis C drugs, AbbVie’s pipeline prospects do not look robust as the company needs to help ensure long-term growth following the Humira patent loss.
George Gutowski writes from a caveat emptor perspective.
FinancialSkeptic's Blog 